A phase 2 trial of HRS-4508 tablet in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07003321 by Jiangsu HengRui Medicine Co., Ltd., with 120 participants planned, started 2025-09-12 and due to reach its primary completion in 2027-09. Interventions recorded: HRS-4508 tablet.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.